FrancophonIA/ELRC3.0 huggingface dataset:
English: ANNEX IV CONDITION OF THE MARKETING AUTHORISATIONS
Maltese: ANNESS IV KUNDIZZJONI TAL-AWTORIZZAZZJONIJIET GĦAT-TQEGĦID FIS-SUQ
English: Risk Management Plan
Maltese: Pjan tal-Ġestjoni tar-Riskji
English: CONDITIONS OF THE MARKETING AUTHORISATIONS National Competent Authorities, coordinated by the Reference Member State where applicable, shall ensure that the following conditions are fulfilled by the Marketing Authorisation Holders:
Maltese: FIS-SUQ L-Awtoritajiet Kompetenti Nazzjonali, ikkoordinati mill-Istat Membru ta' Referenza fejn ikun il-każ, għandhom jiżguraw li l-kundizzjonijiet li ġejjin huma ssodisfati mid-Detenturi tal-Awtorizzazzjoni għat-Tqegħid fis-Suq:
English: Further information on Rhokiinsa can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/rhokiinsa
Maltese: ema.europa.eu/medicines/human/EPAR/rhokiinsa.
English: The active substance in Rhokiinsa, netarsudil, is a Rho kinase inhibitor.
Maltese: Is-sustanza attiva f'Rhokiinsa, in-netarsudil, hija inibitur tal-kinażi Rho.
English: Other common side effects (which may affect up to 2 in 10 people) are: cornea verticillata (deposits in the cornea, the transparent layer in front of the eye that covers the pupil and iris), eye pain, conjunctival haemorrhage (bleeding in the surface layer of the eye), erythema (reddening) at the site where the medicine was applied and the eyelid, corneal staining, blurred vision and increased lacrimation (watery eyes).
Maltese: Effetti sekondarji komuni oħra (li jistgħu jaffettwaw sa żewġ persuni minn kull 10) huma: kornea vertikillata (depożiti fil-kornea, is-saff trasparenti quddiem l-għajn li jkopri l-ħabba u l-iris), uġigħ fl-għajn, emorraġija konġunktivali (fsada fis-saff tal-wiċċ tal-għajn), eritema (ħmura) fis-sit fejn il-mediċina tkun ġiet applikata u t-tebqa tal-għajn, tbajja' fil-kornea, vista mċajpra u żieda fid-dmugħ (għajnejn idemmgħu).
English: Other information about Rhokiinsa
Maltese: Informazzjoni oħra dwar Rhokiinsa
English: Rhokiinsa contains the active substance netarsudil.
Maltese: Rhokiinsa fih is-sustanza attiva netarsudil.
English: In patients with moderately high eye pressure (up to 25 mmHg), Rhokiinsa was as effective as timolol (another medicine), lowering the pressure by around 3.9 mmHg to 4.7 mmHg, compared with reductions of 3.8 mmHg to 5.2 mmHg for patients using timolol.
Maltese: 3.9 mmHg sa 4.7 mmHg, meta mqabbla ma' tnaqqis ta' 3.8 mmHg sa 5.2 mmHg għal pazjenti li jużaw timolol.
English: It is available as an eye-drop solution (200 microgram/ml) and the dose is one drop in the affected eye once a day, in the evening.
Maltese: Jiġi bħala soluzzjoni li titqattar fl-għajn (200 mikrogramma/ml) u d-doża hija qatra waħda fl-għajn affettwata darba kuljum, filgħaxija.
English: What are the risks associated with Rhokiinsa?
Maltese: X'inhuma r-riskji assoċjati ma' Rhokiinsa?
English: Rhokiinsa showed good effects across a range of eye pressures.
Maltese: Rhokiinsa wera effetti tajbin fuq firxa ta' pressjonijiet tal-għajn.
English: In patients whose eye pressure was higher than 25 mmHg, Rhokiinsa was less effective than timolol.
Maltese: F'pazjenti bi pressjoni fl-għajn moderatament għolja (sa 25 mmHg), Rhokiinsa kien effettiv daqs timolol (mediċina oħra), u naqqas il-pressjoni b'madwar
English: As for all medicines, data on the use of Rhokiinsa are continuously monitored.
Maltese: Bħal fil-każ tal-mediċini kollha, id-data dwar l-użu ta' Rhokiinsa hija ssorveljata kontinwament.
English: A main study of 708 patients with open-angle glaucoma or ocular hypertension showed that Rhokiinsa is effective at lowering eye pressure.
Maltese: Studju ewlieni ta' 708 pazjenti bi glawkoma b'angolu miftuħ jew ipertensjoni okulari wera li Rhokiinsa huwa effettiv fit-tnaqqis tal-pressjoni fl-għajn.
English: Rhokiinsa, which has a different mode of action from previously authorised treatments, provides another treatment option for patients with open-angle glaucoma and ocular hypertension.
Maltese: Madankollu, effetti sekondarji fuq l-għajn kienu aktar frekwenti minn dawk ta' timolol, u dan jista' jwassal biex in-nies iwaqqfu l-kura.
English: How is Rhokiinsa used?
Maltese: Rhokiinsa?
English: For the full list of side effects and restrictions with Rhokiinsa, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji u r-restrizzjonijiet b'Rhokiinsa, ara l-fuljett ta' tagħrif.
English: How does Rhokiinsa work?
Maltese: Kif jintuża Rhokiinsa?
English: The safety of Rhokiinsa will be further investigated in a study.
Maltese: Is-sigurtà ta' Rhokiinsa se tiġi investigata aktar fi studju.
English: In terms of safety, the side effects of Rhokiinsa are considered manageable and were more likely to be confined to the eye.
Maltese: F'termini ta' sigurtà, l-effetti sekondarji ta' Rhokiinsa huma kkunsidrati maniġġabbli u kienu aktar probabbli li jkunu ristretti għall-għajn.
English: Why is Rhokiinsa authorised in the EU?
Maltese: Għaliex Rhokiinsa ġie awtorizzat fl-UE?
English: Rhokiinsa is an eye-drop solution that is used to reduce pressure inside the eye in adults who have open-angle glaucoma (a disease where the pressure in the eye rises because fluid cannot drain out of the eye) or ocular hypertension (when the pressure in the eye is higher than normal).
Maltese: Rhokiinsa huwa soluzzjoni ta' taqtir għall-għajn li tintuża biex tnaqqas il-pressjoni ġewwa l-għajn f'adulti li jkollhom glawkoma b'angolu miftuħ (marda fejn il-pressjoni fl-għajn togħla minħabba li lfluwidu ma jkunx jista' joħroġ mill-għajn) jew ipertensjoni okulari (meta l-pressjoni fl-għajn tkun ogħla min-normal).
English: 1 bottle; 2 sachets
Maltese: 1 flixkun; 2 qratas
English: 1 bottle; 1 sachet
Maltese: 1 flixkun; 1 qartas
English: ATCvet code: QI06AJ03.
Maltese: Q106A103.
English: Lyophilisate (10xdose) + solvent (10x1 ml) Lyophilisate (50x1 dose) + solvent (50x1 ml)
Maltese: Lijofiliżat (doża 10x1 ) + solvent (10x1 ml) Lijofiliżat (doża 50x1) + solvent (50x1 ml)
English: 2 egg infective dose 50%
Maltese: 2: doża infettiva tal-bajda 50%
English: Date of first authorisation: 23/02/2005 Date of last renewal: 14/01/2010
Maltese: Data ta' l-aħħar tiġdid: 14/01/2010
English: 1 cell culture infective dose 50%
Maltese: 1: doża infettiva tas-cell culture 50% 2: doża infettiva tal-bajda 50%
English: EU/2/04/050/001 Lyophilisate (10 bottles of 1 dose) + solvent (10 bottles of 1 ml) EU/2/04/050/002 Lyophilisate (50 bottles of 1 dose) + solvent (50 bottles of 1 ml)
Maltese: EU/2/04/050/001 Lijofiliżat (10 fliexken ta' doża ) + solvent (10 fliexken ta' doża) EU/2/04/050/002 Lijofiliżat (50 flixkun ta' doża) + solvent (50 flixkun ta' doża)
English: EXP (mm/yyyy)
Maltese: EXP (xx/ssss)
English: Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) ....................................... ≥ 104.9 CCID501 Inactivated feline calicivirus (FCV 431 and G1 strains) antigens ................................... ≥ 2.0 ELISA U. Attenuated Chlamydophila felis (905 strain) ...................................................................... ≥ 103.0 EID502 Attenuated feline panleucopenia virus (PLI IV) ............................................................. ≥ 103.5 CCID501
Maltese: Virus tal-Ħerpes attenwat tar-rinotrakeite fil-qtates (FHV strejn F2) ............................. ≥ 104.9 CCID501 kalċivirus inattivat fil-qtates (strejn FCV 431 u G1) antiġeni ......................................... ≥ 2.0 ELISA U Chlamydophila felis attenwat (strejn 905) .......................................................................... ≥ 103.0 EID502 Virus attenwat tal-panlewkopenja fil-qtates (PLI IV) ...................................................... ≥ 103.5 CCID501
English: Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) ....................................... ≥ 104.9 CCID501 Inactivated feline calicivirus (FCV 431 and FCV G1 strains) antigens .......................... ≥ 2.0 ELISA U. Attenuated Chlamydophila felis (905 strain) ...................................................................... ≥ 103.0 EID502 Attenuated feline panleucopenia virus (PLI IV) ............................................................. ≥ 103.5 CCID501
Maltese: Virus tal-Ħerpes attenwat tar-rhinotrakeite fil-qtates (FHV strejn F2) ........................... ≥ 104.9 CCID501 kalċivirus inattivat fil-qtates (strejn FCV 431 u G1) antiġeni ........................................ ≥ 2.0 ELISA U. Chlamydophila felis attenwat (strejn 905) .......................................................................... ≥ 103.0 EID502 Virus attenwat tal-panlewkopenja fil-qtates (PLI IV) ...................................................... ≥ 103.5 CCID501
English: Manufacturer responsible for the batch release: MERIAL
Maltese: Manifattur responsabbli għall-ħrug tal-lott: MERIAL
English: Stimulates active immunity against feline rhinotracheitis herpesvirus, feline calicivirus, Chlamydophila felis and feline panleucopenia virus.
Maltese: Tistimola immunità attiva kontra l-virus tal-Ħerpes tar-rinotrakeite fil-qtates, kalċivirus fil-qtates, Chlamydophila felis u l-virus tal-panlewkopenja fil-qtates.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals ) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports).
Maltese: - komuni ħafna (aktar minn wieħed f'10 annimali li juru effetti mhux mixtieqa matul il-perjodu ta' kura waħda) - komuni (aktar minn wieħed iżda inqas minn 10 annimali f'100 annimal) - mhux komuni (aktar minn wieħed iżda inqas minn10 annimali f'1,000 annimal) - rari (aktar minn wieħed iżda inqas minn10 annimali f'10,000 annimal) - rari ħafna (inqas minn annimal wieħed f'10,000 annimal, inklużi rapporti iżolati).
English: Water for injections ..................................................................................................................... q.s.
Maltese: Ilma għal injezzjoni . ...................................................................................................................... q.s. ml 1: doża infettiva tas-cell culture 50%
English: Gentamicin, at most .......................................................................................................................... 28 µg Solvent:
Maltese: Ilma għal injezzjoni ........................................................................................................................ q.s. ml
English: Active immunisation of cats aged 8 weeks and older: - against feline viral rhinotracheitis to reduce clinical signs, - against calicivirus infection to reduce clinical signs, - against Chlamydophila felis infection to reduce clinical signs, - against feline panleucopenia to prevent mortality and clinical signs.
Maltese: Immunizzazzjoni attiva tal-qtates ta' 8 ġimgħat u akbar: - kontra r-rinotrakeite virali fil-qtates biex tnaqqas sinjali kliniċi, - kontra l-infezzjoni tal-kalċivirus biex tnaqqas sinjali kliniċi
English: Excipient:
Maltese: Inkompatibilitajiet:
English: Purevax RCPCh Lyophilisate and solvent for suspension for injection.
Maltese: VETERINARJU Purevax RCPCh lijofiliżat u solvent għal suspensjoni għall-injezzjoni.
English: PACKAGE LEAFLET FOR: Purevax RCPCh lyophilisate and solvent for suspension for injection
Maltese: FIL-PAKKETT: Purevax RCPCh lijofiliżat u solvent għal suspensjoni għall-injezzjoni.
English: Lyophilisate and solvent for suspension for injection.
Maltese: Lijofiliżat u solvent għal suspensjoni għall-injezzjoni.
English: Name and address of the manufacturers of the biological active substances
Maltese: MANIFATTURITAS-SUSTANZI BIJOLOĠIĊI ATTIVI
English: Revaccination: - the first revaccination must be carried out for all components one year after the primary vaccination course, - subsequent revaccinations must be carried out: every year for the chlamydiosis component and at intervals of up to three years for the rhinotracheitis, calicivirosis and panleucopenia components.
Maltese: Ripetizzjoni tal-vaċċinazzjoni: - l-ewwel ripetizzjoni tal-vaċċinazzjoni għandha tingħata għall-komponenti kollha sena wara l-ewwel kors ta' vaċċinazzjoni , - tilqim sussegwenti għandhom jingħataw kull sena għall-komponent tal-klamidjosi, u f'intervalli sa tliet snin għall-komponenti tar-rinotrakeite, tal-kalċivirosi u tal-panlewkopenja.
English: Where high levels of maternal antibodies against rhinotracheitis, calicivirosis, panleucopenia or Chlamydophila components are expected to be present (e.g. in kittens of 9-12 weeks of age born from queens which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age.
Maltese: Fejn livelli għolja ta' antikorpi materni kontra l-komponenti tar-rinotrakeite, kalċivirosi, panlewkopenja jew Chlamydophila huma mistennija li jkunu preżenti (per eżempju fi frieħ ta' bejn 9 u 12-il ġimgħa mwielda minn nisa li kienu mlaqqma qabel it-tqala u/jew kellhom espożizzjoni preċedenti magħrufa jew issuspettata għall-patoġenu/patoġeni), l-ewwel kors ta' tilqima għandu jiġi rimandat sal-età ta' 12-il ġimgħa.
English: Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus, Chlamydophila felis and panleucopenia components.
Maltese: Ġie muri li l-bidu tal-immunità jseħħ ġimgħa wara l-ewwel kors ta' vaċċinazzjoni għall-komponenti tar-rinotrakeite, kalċivirus, Chlamydophila felis u panlewkopenja.
English: * less than 1 animal in 10,000 animals displaying adverse reaction(s) during the course of one treatment, including isolated reports.
Maltese: *inqas minn annimal wieħed f'kull 10,000 juri effetti mhux mixtieqa waqt il-kors ta' kura waħda, inklużi rapporti iżolati.
English: FCV (431 and G1 strains) ............................................................................................... ≥ 2.0 ELISA U. Chlamydophila felis (905 strain) .......................................................................................... ≥ 103.0 EID50
Maltese: FHV (strejn F2) ................................................................................................................ ≥ 104.9 CCID501 FCV (strejn 431 u G1) .................................................................................................... ≥ 2.0 ELISA U. Chlamydophila felis (strejn 905) ........................................................................................ ≥ 103.0 EID502 FPV (PLI IV) ......................................................................
English: Pack containing 50 bottles of 1 dose of lyophilisate and 50 bottles of 1 ml of solvent.
Maltese: Pakkett li għandu 50 flixkun ta' lijofiliżat u 50 flixkun ta' solvent
English: Name and address of the manufacturer responsible for batch release
Maltese: TAL-MANIFATTURA RESPONSABBLI MILL
English: ATCvet code: QA07AA92.
Maltese: QA07AA92.
English: de la Industria, nº 30 Polígono Industrial de Alcobendas 28108 Alcobendas (Madrid)
Maltese: Polígono Industrial de Alcobendas 28108 Alcobendas (Madrid)
English: D-61352 Bad
Maltese: D-61352 Bad Homburg
English: 'Salmonella Dublin in Irish cattle' Vet Ireland J 4:642-3
Maltese: Dublin in Irish cattle' Vet Ireland J 4:642-3
English: Res. Vol. 4(9), pp. 796-800
Maltese: Vol. 4(9), pp. 796-800
English: Germany Lilly Deutschland GmbH
Maltese: Lilly Deutschland GmbH
English: Fracção A/D 1500-392 Lisboa Portugal
Maltese: 1500-392 Lisboa Portugal
English: IU (bag)
Maltese: IU (borża)
English: Eli Lilly Italia SpA Via A. Gramsci,
Maltese: Eli Lilly Italia SpA Via A.
English: 'Observation on the occurrence and transmission pattern of Salmonella gallinarum in commercial poultry farms in Ogun State, South Western Nigeria.'
Maltese: ‘Observation on the occurrence and transmission pattern of Salmonella gallinarum in commercial poultry farms in Ogun State, South Western Nigeria.' Afr. J. Microbiol.
English: Apramycin ……………………………552,000 IU* (as apramycin sulfate) * IU - international units
Maltese: Apramycin ……………………………552,000 IU* (bħala apramycin sulfate)
English: Apramycin is effective against Gram-negative bacteria (Salmonella and Escherichia coli).
Maltese: Apramycin hu effettiv kontra batterji Gram-negattivi (Salmonella u Escherichia coli).
English: IU 2 x 106 IU
Maltese: 1 x 106 IU 2 x 106 IU
English: Critically important antimicrobials for human medicine - 5th rev. Geneva.
Maltese: World Health Organization (2017). Critically important antimicrobials for human medicine - 5th rev.
English: Torre Ocidente Rua Galileu Galilei, N.º 2, Piso 7
Maltese: Farmacêuticos, Lda Torre Ocidente Rua Galileu Galilei, N.º 2, Piso 7 Fracção A/D
English: 'Diagnosis and control of Salmonella Dublin in dairy herds' In Practice 39:158-168.
Maltese: 6 Henderson, K. and Mason, C. 2017. ‘Diagnosis and control of Salmonella Dublin in dairy herds' In Practice 39:158-168.
English: O´Leary, C. 2014.
Maltese: O´Leary, C. 2014. ‘Salmonella
English: Apramycin sulfate 333 mg/ml equivalent to apramycin 230 mg/ml
Maltese: Apramycin sulfate 333 mg/ml ekwivalenti għal apramycin 230 mg/ml
English: Elanco Europe Ltd Lilly House Priestley Road Basingstoke RG24 9NL United Kingdom
Maltese: L-Olanda Elanco Europe Ltd Lilly House Priestley Road Basingstoke RG24 9NL
English: Denmark Elanco Animal Health A/S
Maltese: Elanco Animal Health A/S
English: EFSA (European Food Safety Authority) and ECDC (European Centre for Disease Prevention and Control), 2016.
Maltese: Husb 1(3): 301. doi: 4 EFSA (European Food Safety Authority) and ECDC (European Centre for Disease Prevention and Control), 2016.
English: PACKAGE SIZE 50 x 106 IU (bottle) 1,000 x 10
Maltese: DAQS TAL-PAKKETT 50 x 106 IU (flixkun) 1,000 x 10
English: DK-2730 Herlev Denmark
Maltese: DK-2730
English: PACKAGE SIZE 50 sachets
Maltese: DAQS TAL-PAKKETT 50 qartas
English: Pharmacotherapeutic group: Intestinal antiinfectives, antibiotics.
Maltese: Antiinfettivi intestinali, antibijotiċi.
English: Lyskær 3E, 2 tv.
Maltese: Eli Lilly Danmark A/S Lyskær 3E, 2 tv.
English: Resistance mechanisms: Different aminoglycoside 3-N acetyltransferase enzymes (AAC-3) have been related with resistance to apramycin.
Maltese: Enzimi differenti ta' aminoglycoside 3-N acetyltransferase enzymes (AAC-3)
English: Abt. Elanco Animal Health
Maltese: Elanco Animal Health
English: Regulation (EC) No 2160/2003 of the European Parliament and of the Council as regards requirements for the use of specific control methods in the framework of the national programs for the control of salmonella in poultry - link 10 Regulation (EC) No 1177/2006 implementing Regulation (EC) No 2160/2003 of the European Parliament and of the
Maltese: Regulation (EC) No 1177/2006 implementing Regulation (EC) No 2160/2003 of the European Parliament and of the Council as regards requirements for the use of specific control methods in the framework of the national programmes for the control of salmonella in poultry - link
English: 4-ply polyethylene terephthalate (PET)/polyethylene/aluminium foil/surlyn ionomer sachet, sealed by heat and pressure.
Maltese: Qartas tal-polyethylene terephthalate (PET)/polyethylene/fojl tal-aluminju/surlyn ionomer b'4 saffi,
English: 'Pork Meat as a Potential Source of Salmonella enterica subsp.
Maltese: ‘Pork Meat as a Potential Source of Salmonella enterica subsp. arizonae Infection in Humans' J. Clin.
English: Possible intoxications can be recognised by the following symptoms: soft faeces, diarrhoea, vomiting (weight loss, anorexia, and similar), renal impairment and effects on the central nervous system (reduced activity, loss of reflexes, convulsions, etc.).
Maltese: Intossikazzjonijiet possibbli jistgħu jintgħarfu mis-sintomi li ġejjin: ippurgar artab, dijarea, rimettar (telf ta' piż, anoressija, u sintomi simili), indeboliment tal-kliewi u effetti fuq is-sistema nervuża ċentrali (attività mnaqqsa, telf tar-riflessi, konvulżjonijiet, eċċ.).
English: Aminoglycosides may have a negative influence on the kidney function.
Maltese: L-aminoglycosides jista' jkollhom influwenza negattiva fuq il-funzjoni tal-kliewi.
English: SPC section 6.3
Maltese: Sezzjoni 6.3 tal-SPC
English: Preruminant calves, pigs, broilers
Maltese: Għoġġiela preruminanti, qżieqeż, broilers
English: Some strains of Salmonella Typhimurium DT104 in addition to resistance against betalactams, streptomycin, tetracyclines and sulphonamides carry a conjugative resistance plasmid against apramycin.
Maltese: Xi razez ta' Salmonella Typhimurium DT104 flimkien ma' reżistenza kontra beta-lactams, streptomycin, tetracyclines u sulphonamides, iġorru reżistenza konjugattiva plażmid kontra apramycin.
English: Eli Lilly and Company Limited Elanco Animal Health
Maltese: Eli Lilly and Company Limited
English: 1 g powder contains 500 mg apramycin as apramycin sulfate in 2.2 ml equivalent to 1 g powder
Maltese: 1 g ta' trab fih 500 mg ta' apramycin bħala apramycin sulfate fi 2.2 mL ekwivalenti għal 1 g ta' trab
English: It was demonstrated that 22 to 44 mg apramycin per kg bw during 5-10 consecutive days resulted in effective therapy against experimental salmonellosis in calves.
Maltese: Intwera li 22 sa 44 mg apramiċina per kg bw matul 5-10 ijiem konsekuttivi rriżulta f'terapija effettiva kontra ssalmonellożi sperimentali fl-għoġġiela.
English: However, recent publications in the scientific literature indicate that the disease is present in cattle in Europe, e.g. in Ireland (O´Leary, 20145) and the UK (Henderson and Mason, 20176).
Maltese: Madankollu, pubblikazzjonijiet riċenti fil-letteratura xjentifika jindikaw li l-marda hija preżenti fil-frat flEwropa, eż. fl-Irlanda (O´Leary, 20145) u fir-Renju Unit (Henderson u Mason, 20176).
English: Calves have been authorised in Denmark, France, Ireland, the Netherlands, Portugal, Spain and the UK.
Maltese: L-għoġġiela ġew awtorizzati fid-Danimarka, fi Franza, fl-Irlanda, fin-Netherlands, fil-Portugall, fi Spanja u fir-Renju Unit.
English: EFSA Journal 2017;15(8):4954, 50 pp. https://doi.org/10.2903/j.efsa.2017.4954
Maltese: Gallinarum and S. arizonae). EFSA Journal 2017;15(8):4954, 50 pp. https://doi.org/10.2903/j.efsa.2017.4954 14 World Health Organization (2017). Critically important antimicrobials for human medicine - 5th rev.
English: The dosages of apramycin base or apramycin sulfate used were 0, 5.5, 11, 22 and/or 44 mg/kg bw/day during 5 or 10 consecutive days.
Maltese: Id-dożaġġi ta' bażi tal-apramiċina jew is-sulfat talapramiċina li ntużaw kienu 0, 5.5, 11, 22 u/jew 44 mg/kg bw/jum matul 5 jew 10 ijiem konsekuttivi.
English: 1 g powder contains 1 g apramycin (as sulfate)
Maltese: 1 g ta' trab fih 1 g ta' apramycin (bħala sulfate)
English: Apramycin is a broad-spectrum aminocyclitol antibiotic produced by a strain of Streptomyces tenebrarius.
Maltese: Lapramiċina hija antibijotiku aminoċiklitol ta' spettru wiesa' prodott minn razza ta' Streptomyces tenebrarius.
English: 100 g powder contain 100 g apramycin sulfate
Maltese: 100 g ta' trab fih 100 g ta' apramycin sulfate
English: Council as regards requirements for the use of specific control methods in the framework of the national programmes for the control of salmonella in poultry - link disease caused by Salmonella Pullorum is considered an exceptional circumstance that would require to treat (or slaughter) clinically affected flocks.
Maltese: Council as regards requirements for the use of specific control methods in the framework of the national programmes for the control of salmonella in poultry - link
English: Additional data provided from 2014 indicate that Salmonella Dublin was mostly susceptible to apramycin (96.5% of isolates susceptible to all antimicrobials in the panel, including apramycin).
Maltese: Data addizzjonali pprovduta mill-2014 tindika li Salmonella Dublin kienet l-aktar suxxettibbli għall-apramiċina (96.5% tal-iżolati suxxettibbli għall-antimikrobiċi kollha fil-pannell, inkluż l-apramiċina).